Peripheral Neuropathy Treatment Market 2024-2028

Report
175 Pages
June 2024
Region: Global
TechNavio
ID: 5188677

The peripheral neuropathy treatment market is forecasted to grow by USD 447.3 million during 2023-2028, accelerating at a CAGR of 4.36% during the forecast period. The report on the peripheral neuropathy treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of peripheral neuropathy, recent drug approvals for peripheral neuropathy, and rising awareness of peripheral neuropathy.

The peripheral neuropathy treatment market is segmented as below:

By Type

Diabetic peripheral neuropathy
Chemotherapy induced peripheral neuropathy
Others

By Therapy

Pharmacological therapies
Non pharmacological therapies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strong drug pipeline as one of the prime reasons driving the peripheral neuropathy treatment market growth during the next few years. Also, technological advances with new formulations of drugs and rising penetration of generic drugs will lead to sizable demand in the market.

The report on the peripheral neuropathy treatment market covers the following areas:

Peripheral neuropathy treatment market sizing
Peripheral neuropathy treatment market forecast
Peripheral neuropathy treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading peripheral neuropathy treatment market vendors that include Apotex Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Cadila Pharmaceuticals Ltd., Cipla Inc., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Grunenthal GmbH, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc. Also, the peripheral neuropathy treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
Executive Summary - Chart on Market Overview
Executive Summary - Data Table on Market Overview
Executive Summary - Chart on Global Market Characteristics
Executive Summary - Chart on Market By Geographical Landscape
Executive Summary - Chart on Market Segmentation by Type
Executive Summary - Chart on Market Segmentation by Therapy
Executive Summary - Chart on Incremental Growth
Executive Summary - Data Table on Incremental Growth
Executive Summary - Chart on Company Market Positioning

2 Market Landscape

2.1 Market ecosystem
Parent Market
Data Table on - Parent Market
2.2 Market characteristics
Market characteristics analysis
2.3 Value chain analysis
Value Chain Analysis

3 Market Sizing

3.1 Market definition
Offerings of companies included in the market definition
3.2 Market segment analysis
Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Chart on Global - Market size and forecast 2023-2028 ($ million)
Data Table on Global - Market size and forecast 2023-2028 ($ million)
Chart on Global Market: Year-over-year growth 2023-2028 (%)
Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global Peripheral Neuropathy Treatment Market 2018 - 2022
Historic Market Size - Data Table on Global Peripheral Neuropathy Treatment Market 2018 - 2022 ($ million)
4.2 Type segment analysis 2018 - 2022
Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.3 Therapy segment analysis 2018 - 2022
Historic Market Size - Therapy Segment 2018 - 2022 ($ million)
4.4 Geography segment analysis 2018 - 2022
Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country segment analysis 2018 - 2022
Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
Chart on Type - Market share 2023-2028 (%)
Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Chart on Comparison by Type
Data Table on Comparison by Type
6.3 Diabetic peripheral neuropathy - Market size and forecast 2023-2028
Chart on Diabetic peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Data Table on Diabetic peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Chart on Diabetic peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2023-2028 (%)
6.4 Chemotherapy induced peripheral neuropathy - Market size and forecast 2023-2028
Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2023-2028 (%)
6.5 Others - Market size and forecast 2023-2028
Chart on Others - Market size and forecast 2023-2028 ($ million)
Data Table on Others - Market size and forecast 2023-2028 ($ million)
Chart on Others - Year-over-year growth 2023-2028 (%)
Data Table on Others - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Type
Market opportunity by Type ($ million)
Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Therapy

7.1 Market segments
Chart on Therapy - Market share 2023-2028 (%)
Data Table on Therapy - Market share 2023-2028 (%)
7.2 Comparison by Therapy
Chart on Comparison by Therapy
Data Table on Comparison by Therapy
7.3 Pharmacological therapies - Market size and forecast 2023-2028
Chart on Pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Data Table on Pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Chart on Pharmacological therapies - Year-over-year growth 2023-2028 (%)
Data Table on Pharmacological therapies - Year-over-year growth 2023-2028 (%)
7.4 Non pharmacological therapies - Market size and forecast 2023-2028
Chart on Non pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Data Table on Non pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Chart on Non pharmacological therapies - Year-over-year growth 2023-2028 (%)
Data Table on Non pharmacological therapies - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Therapy
Market opportunity by Therapy ($ million)
Data Table on Market opportunity by Therapy ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Chart on Market share By Geographical Landscape 2023-2028 (%)
Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Chart on Geographic comparison
Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Chart on North America - Market size and forecast 2023-2028 ($ million)
Data Table on North America - Market size and forecast 2023-2028 ($ million)
Chart on North America - Year-over-year growth 2023-2028 (%)
Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Chart on Europe - Market size and forecast 2023-2028 ($ million)
Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Chart on Europe - Year-over-year growth 2023-2028 (%)
Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Chart on Asia - Market size and forecast 2023-2028 ($ million)
Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Chart on Asia - Year-over-year growth 2023-2028 (%)
Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Chart on US - Market size and forecast 2023-2028 ($ million)
Data Table on US - Market size and forecast 2023-2028 ($ million)
Chart on US - Year-over-year growth 2023-2028 (%)
Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Chart on Germany - Market size and forecast 2023-2028 ($ million)
Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Chart on Germany - Year-over-year growth 2023-2028 (%)
Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Chart on China - Market size and forecast 2023-2028 ($ million)
Data Table on China - Market size and forecast 2023-2028 ($ million)
Chart on China - Year-over-year growth 2023-2028 (%)
Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Chart on UK - Market size and forecast 2023-2028 ($ million)
Data Table on UK - Market size and forecast 2023-2028 ($ million)
Chart on UK - Year-over-year growth 2023-2028 (%)
Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 Japan - Market size and forecast 2023-2028
Chart on Japan - Market size and forecast 2023-2028 ($ million)
Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Chart on Japan - Year-over-year growth 2023-2028 (%)
Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Market opportunity By Geographical Landscape ($ million)
Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Opportunity/Restraints

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Impact of drivers and challenges in 2023 and 2028
10.4 Market opportunities/restraints

11 Competitive Landscape

11.1 Overview
11.2 Competitive Landscape
Overview on criticality of inputs and factors of differentiation
11.3 Landscape disruption
Overview on factors of disruption
11.4 Industry risks
Impact of key risks on business

12 Competitive Analysis

12.1 Companies profiled
Companies covered
12.2 Market positioning of companies
Matrix on companies position and classification
12.3 Apotex Inc.
Apotex Inc. - Overview
Apotex Inc. - Product / Service
Apotex Inc. - Key news
Apotex Inc. - Key offerings
12.4 ASSERTIO HOLDINGS INC.
ASSERTIO HOLDINGS INC. - Overview
ASSERTIO HOLDINGS INC. - Product / Service
ASSERTIO HOLDINGS INC. - Key offerings
12.5 AstraZeneca Plc
AstraZeneca Plc - Overview
AstraZeneca Plc - Product / Service
AstraZeneca Plc - Key news
AstraZeneca Plc - Key offerings
12.6 Cadila Pharmaceuticals Ltd.
Cadila Pharmaceuticals Ltd. - Overview
Cadila Pharmaceuticals Ltd. - Product / Service
Cadila Pharmaceuticals Ltd. - Key offerings
12.7 Cipla Inc.
Cipla Inc. - Overview
Cipla Inc. - Business segments
Cipla Inc. - Key news
Cipla Inc. - Key offerings
Cipla Inc. - Segment focus
12.8 Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Co. Ltd. - Overview
Daiichi Sankyo Co. Ltd. - Product / Service
Daiichi Sankyo Co. Ltd. - Key news
Daiichi Sankyo Co. Ltd. - Key offerings
12.9 Dr Reddys Laboratories Ltd.
Dr Reddys Laboratories Ltd. - Overview
Dr Reddys Laboratories Ltd. - Business segments
Dr Reddys Laboratories Ltd. - Key news
Dr Reddys Laboratories Ltd. - Key offerings
Dr Reddys Laboratories Ltd. - Segment focus
12.10 Eli Lilly and Co.
Eli Lilly and Co. - Overview
Eli Lilly and Co. - Product / Service
Eli Lilly and Co. - Key news
Eli Lilly and Co. - Key offerings
12.11 Endo International Plc
Endo International Plc - Overview
Endo International Plc - Business segments
Endo International Plc - Key news
Endo International Plc - Key offerings
Endo International Plc - Segment focus
12.12 Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc - Overview
Hikma Pharmaceuticals Plc - Business segments
Hikma Pharmaceuticals Plc - Key news
Hikma Pharmaceuticals Plc - Key offerings
Hikma Pharmaceuticals Plc - Segment focus
12.13 Johnson and Johnson Services Inc.
Johnson and Johnson Services Inc. - Overview
Johnson and Johnson Services Inc. - Business segments
Johnson and Johnson Services Inc. - Key news
Johnson and Johnson Services Inc. - Key offerings
Johnson and Johnson Services Inc. - Segment focus
12.14 Lupin Ltd.
Lupin Ltd. - Overview
Lupin Ltd. - Product / Service
Lupin Ltd. - Key news
Lupin Ltd. - Key offerings
12.15 Novartis AG
Novartis AG - Overview
Novartis AG - Business segments
Novartis AG - Key news
Novartis AG - Key offerings
Novartis AG - Segment focus
12.16 Pfizer Inc.
Pfizer Inc. - Overview
Pfizer Inc. - Product / Service
Pfizer Inc. - Key news
Pfizer Inc. - Key offerings
12.17 Viatris Inc.
Viatris Inc. - Overview
Viatris Inc. - Business segments
Viatris Inc. - Key news
Viatris Inc. - Key offerings
Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Inclusions checklist
Exclusions checklist
13.3 Currency conversion rates for US$
Currency conversion rates for US$
13.4 Research methodology
Research methodology
13.5 Data procurement
Information sources
13.6 Data validation
Data validation
13.7 Validation techniques employed for market sizing
Validation techniques employed for market sizing
13.8 Data synthesis
Data synthesis
13.9 360 degree market analysis
360 degree market analysis
13.10 List of abbreviations
List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Therapy
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Company Market Positioning
Exhibits 10: Parent Market
Exhibits 11: Data Table on - Parent Market
Exhibits 12: Market characteristics analysis
Exhibits 13: Value Chain Analysis
Exhibits 14: Offerings of companies included in the market definition
Exhibits 15: Market segments
Exhibits 16: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 17: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 18: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 19: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 20: Historic Market Size - Data Table on Global Peripheral Neuropathy Treatment Market 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Therapy Segment 2018 - 2022 ($ million)
Exhibits 23: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 24: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 25: Five forces analysis - Comparison between 2023 and 2028
Exhibits 26: Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 29: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 30: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 31: Chart on Market condition - Five forces 2023 and 2028
Exhibits 32: Chart on Type - Market share 2023-2028 (%)
Exhibits 33: Data Table on Type - Market share 2023-2028 (%)
Exhibits 34: Chart on Comparison by Type
Exhibits 35: Data Table on Comparison by Type
Exhibits 36: Chart on Diabetic peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibits 37: Data Table on Diabetic peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibits 38: Chart on Diabetic peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Exhibits 39: Data Table on Diabetic peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Exhibits 40: Chart on Chemotherapy induced peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibits 41: Data Table on Chemotherapy induced peripheral neuropathy - Market size and forecast 2023-2028 ($ million)
Exhibits 42: Chart on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Exhibits 43: Data Table on Chemotherapy induced peripheral neuropathy - Year-over-year growth 2023-2028 (%)
Exhibits 44: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 45: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits 46: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 47: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 48: Market opportunity by Type ($ million)
Exhibits 49: Data Table on Market opportunity by Type ($ million)
Exhibits 50: Chart on Therapy - Market share 2023-2028 (%)
Exhibits 51: Data Table on Therapy - Market share 2023-2028 (%)
Exhibits 52: Chart on Comparison by Therapy
Exhibits 53: Data Table on Comparison by Therapy
Exhibits 54: Chart on Pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Exhibits 55: Data Table on Pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Exhibits 56: Chart on Pharmacological therapies - Year-over-year growth 2023-2028 (%)
Exhibits 57: Data Table on Pharmacological therapies - Year-over-year growth 2023-2028 (%)
Exhibits 58: Chart on Non pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Exhibits 59: Data Table on Non pharmacological therapies - Market size and forecast 2023-2028 ($ million)
Exhibits 60: Chart on Non pharmacological therapies - Year-over-year growth 2023-2028 (%)
Exhibits 61: Data Table on Non pharmacological therapies - Year-over-year growth 2023-2028 (%)
Exhibits 62: Market opportunity by Therapy ($ million)
Exhibits 63: Data Table on Market opportunity by Therapy ($ million)
Exhibits 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 65: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 66: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 67: Chart on Geographic comparison
Exhibits 68: Data Table on Geographic comparison
Exhibits 69: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 70: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 71: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 72: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 73: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 74: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 75: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 76: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 77: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 78: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 79: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 80: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 81: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 82: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 83: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 84: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 85: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 86: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 87: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 88: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 89: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 90: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 91: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 92: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 93: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 94: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 95: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 96: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 97: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 98: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 99: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 100: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 101: Chart on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 102: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
Exhibits 103: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 104: Data Table on Japan - Year-over-year growth 2023-2028 (%)
Exhibits 105: Market opportunity By Geographical Landscape ($ million)
Exhibits 106: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 107: Impact of drivers and challenges in 2023 and 2028
Exhibits 108: Overview on criticality of inputs and factors of differentiation
Exhibits 109: Overview on factors of disruption
Exhibits 110: Impact of key risks on business
Exhibits 111: Companies covered
Exhibits 112: Matrix on companies position and classification
Exhibits 113: Apotex Inc. - Overview
Exhibits 114: Apotex Inc. - Product / Service
Exhibits 115: Apotex Inc. - Key news
Exhibits 116: Apotex Inc. - Key offerings
Exhibits 117: ASSERTIO HOLDINGS INC. - Overview
Exhibits 118: ASSERTIO HOLDINGS INC. - Product / Service
Exhibits 119: ASSERTIO HOLDINGS INC. - Key offerings
Exhibits 120: AstraZeneca Plc - Overview
Exhibits 121: AstraZeneca Plc - Product / Service
Exhibits 122: AstraZeneca Plc - Key news
Exhibits 123: AstraZeneca Plc - Key offerings
Exhibits 124: Cadila Pharmaceuticals Ltd. - Overview
Exhibits 125: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibits 126: Cadila Pharmaceuticals Ltd. - Key offerings
Exhibits 127: Cipla Inc. - Overview
Exhibits 128: Cipla Inc. - Business segments
Exhibits 129: Cipla Inc. - Key news
Exhibits 130: Cipla Inc. - Key offerings
Exhibits 131: Cipla Inc. - Segment focus
Exhibits 132: Daiichi Sankyo Co. Ltd. - Overview
Exhibits 133: Daiichi Sankyo Co. Ltd. - Product / Service
Exhibits 134: Daiichi Sankyo Co. Ltd. - Key news
Exhibits 135: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibits 136: Dr Reddys Laboratories Ltd. - Overview
Exhibits 137: Dr Reddys Laboratories Ltd. - Business segments
Exhibits 138: Dr Reddys Laboratories Ltd. - Key news
Exhibits 139: Dr Reddys Laboratories Ltd. - Key offerings
Exhibits 140: Dr Reddys Laboratories Ltd. - Segment focus
Exhibits 141: Eli Lilly and Co. - Overview
Exhibits 142: Eli Lilly and Co. - Product / Service
Exhibits 143: Eli Lilly and Co. - Key news
Exhibits 144: Eli Lilly and Co. - Key offerings
Exhibits 145: Endo International Plc - Overview
Exhibits 146: Endo International Plc - Business segments
Exhibits 147: Endo International Plc - Key news
Exhibits 148: Endo International Plc - Key offerings
Exhibits 149: Endo International Plc - Segment focus
Exhibits 150: Hikma Pharmaceuticals Plc - Overview
Exhibits 151: Hikma Pharmaceuticals Plc - Business segments
Exhibits 152: Hikma Pharmaceuticals Plc - Key news
Exhibits 153: Hikma Pharmaceuticals Plc - Key offerings
Exhibits 154: Hikma Pharmaceuticals Plc - Segment focus
Exhibits 155: Johnson and Johnson Services Inc. - Overview
Exhibits 156: Johnson and Johnson Services Inc. - Business segments
Exhibits 157: Johnson and Johnson Services Inc. - Key news
Exhibits 158: Johnson and Johnson Services Inc. - Key offerings
Exhibits 159: Johnson and Johnson Services Inc. - Segment focus
Exhibits 160: Lupin Ltd. - Overview
Exhibits 161: Lupin Ltd. - Product / Service
Exhibits 162: Lupin Ltd. - Key news
Exhibits 163: Lupin Ltd. - Key offerings
Exhibits 164: Novartis AG - Overview
Exhibits 165: Novartis AG - Business segments
Exhibits 166: Novartis AG - Key news
Exhibits 167: Novartis AG - Key offerings
Exhibits 168: Novartis AG - Segment focus
Exhibits 169: Pfizer Inc. - Overview
Exhibits 170: Pfizer Inc. - Product / Service
Exhibits 171: Pfizer Inc. - Key news
Exhibits 172: Pfizer Inc. - Key offerings
Exhibits 173: Viatris Inc. - Overview
Exhibits 174: Viatris Inc. - Business segments
Exhibits 175: Viatris Inc. - Key news
Exhibits 176: Viatris Inc. - Key offerings
Exhibits 177: Viatris Inc. - Segment focus
Exhibits 178: Inclusions checklist
Exhibits 179: Exclusions checklist
Exhibits 180: Currency conversion rates for US$
Exhibits 181: Research methodology
Exhibits 182: Information sources
Exhibits 183: Data validation
Exhibits 184: Validation techniques employed for market sizing
Exhibits 185: Data synthesis
Exhibits 186: 360 degree market analysis
Exhibits 187: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global peripheral neuropathy treatment market: Apotex Inc., ASSERTIO HOLDINGS INC., AstraZeneca Plc, Cadila Pharmaceuticals Ltd., Cipla Inc., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., Endo International Plc, Grunenthal GmbH, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Novartis AG, Pfizer Inc., SHIONOGI Co. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is strong drug pipeline."

According to the report, one of the major drivers for this market is the increasing prevalence of peripheral neuropathy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Apotex Inc.
ASSERTIO HOLDINGS INC.
AstraZeneca Plc
Cadila Pharmaceuticals Ltd.
Cipla Inc.
Daiichi Sankyo Co. Ltd.
Dr Reddys Laboratories Ltd.
Eli Lilly and Co.
Endo International Plc
Grunenthal GmbH
Hikma Pharmaceuticals Plc
Johnson and Johnson Services Inc.
Lupin Ltd.
Novartis AG
Pfizer Inc.
SHIONOGI Co. Ltd.
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
UCB SA
Viatris Inc.

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2481EUR$2,500USD£2,058GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€3969EUR$4,000USD£3,293GBP

The peripheral neuropathy treatment market is segmented as below:

By Type

By Therapy

By Geographical Landscape

The report on the peripheral neuropathy treatment market covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Peripheral Neuropathy Global Market Report 2024

Chemotherapy Induced Peripheral Neuropathy Treatment Market by Treatment Types, Stages Of Treatment, Patient Demographics, Treatment Settings, Duration Of Treatment, Drug Mechanism Of Action - Global Forecast 2025-2030

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024

Chemotherapy-Induced Peripheral Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Peripheral Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2030

About the Neuropathy Drug Market